Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nevxal Forte
- Development stage
- Unknown
- Lead developer
- Orchidia Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Nevxal Forte is a topical ophthalmic suspension containing nepafenac, a nonsteroidal anti-inflammatory drug (NSAID) prodrug. Developed and manufactured by Orchidia Pharmaceutical, it is indicated for the prevention and treatment of pain and inflammation associated with cataract surgery. Upon administration, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases into amfenac, a potent inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. This inhibition reduces the synthesis of prostaglandins, which are key mediators of ocular inflammation and pain. The formulation is typically preserved with benzalkonium chloride and is marketed primarily in Egypt and surrounding regions.
- Brand names
- Nevxal Forte
- Other names
- nepafenac ophthalmic suspension
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Nevxal Forte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nevxal Forte.